STRIBILD (emtricitabine, cobicistat, elvitegravir and tenofovir disoproxil fumarate), antiviral combination

Insufficient clinical benefit to justify its reimbursement for the treatment of HIV in adolescents aged 12 – 18 years-old

• STRIBILD now has MA for the treatment of HIV-1 infection in adolescents 12 to 18 years-old, weighing at least 35 kg, without known resistance mutation to one of the three antiretroviral agents contained in STRIBILD and having presented with toxicity preventing the use of other treatments not containing tenofovir disoproxil fumarate.

• It has no role in the therapeutic strategy for this population.